{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:27:15Z","timestamp":1791412035890,"version":"4.3.3"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["75F40120F19003"],"award-info":[{"award-number":["75F40120F19003"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["HHSF223201810022I"],"award-info":[{"award-number":["HHSF223201810022I"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.vaccine.2022.11.003","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T02:10:51Z","timestamp":1667873451000},"page":"333-353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019\u20132020"],"prefix":"10.1016","volume":"41","author":[{"given":"Keran","family":"Moll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Lufkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn R.","family":"Fingar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Ke Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Tworkoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chianti","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayan","family":"Hobbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minya","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian","family":"McCarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanlai","family":"Shangguan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Burrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoganand","family":"Chillarige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Beers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Saunders-Hastings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Muthuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Kelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kandace L.","family":"Amend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djeneba Audrey","family":"Djibo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Beachler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel P.","family":"Ogilvie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Secora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl N.","family":"McMahill-Walraven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Seeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rositsa","family":"Dimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"MaCurdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Obidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Forshee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Lee","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Shoaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.11.003_b0005","unstructured":"World Health Organization. WHO Director-General's statement on IHR Emergency Committee on Novel Coronavirus (2019-nCoV). https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-statement-on-ihr-emergency-committee-on-novel-coronavirus-(2019-ncov); 30 January 2020 [accessed 28 March 2022]."},{"key":"10.1016\/j.vaccine.2022.11.003_b0010","unstructured":"World Health Organization. WHO Coronavirus (COVID-19) Dashboard. https:\/\/covid19.who.int\/; last updated 23 June 2022 [accessed 23 June 2022]."},{"key":"10.1016\/j.vaccine.2022.11.003_b0015","unstructured":"COVID-19 Vaccine Tracker. United States of America, https:\/\/covid19.trackvaccines.org\/country\/united-states-of-america\/; last updated 28 March 2022 [accessed 28 March 2022]."},{"issue":"19","key":"10.1016\/j.vaccine.2022.11.003_b0020","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.vaccine.2021.03.016","article-title":"The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety","volume":"39","author":"Black","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.11.003_b0025","unstructured":"Council for International Organizations of Medical Sciences. CIOMS Cumulative Pharmacovigilance Glossary Version 1.0, https:\/\/cioms.ch\/wp-content\/uploads\/2021\/03\/CIOMS-Cumulative-PV-Glossary-v1.0.pdf; 25 March 2021 [accessed 11 April 2022]."},{"key":"10.1016\/j.vaccine.2022.11.003_b0030","unstructured":"U.S. Food and Drug Administration. COVID-19 vaccine safety surveillance. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/covid-19-vaccine-safety-surveillance; 7 December 2021 [accessed 28 March 2022]."},{"key":"10.1016\/j.vaccine.2022.11.003_b0035","article-title":"Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study","volume":"373","author":"Li","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2022.11.003_b0040","doi-asserted-by":"crossref","unstructured":"Cantor JH, Sood N, Bravata D, Pera M, Whaley CM. The impact of the COVID-19 pandemic and policy response on health care utilization: evidence from county-level medical claims and cellphone data. https:\/\/www.nber.org\/papers\/w28131; November 2020 [accessed 28 March 2022].","DOI":"10.3386\/w28131"},{"key":"10.1016\/j.vaccine.2022.11.003_b0045","doi-asserted-by":"crossref","first-page":"795","DOI":"10.15585\/mmwr.mm6925e2","article-title":"Potential indirect effects of the COVID-19 pandemic on use of emergency departments for acute life-threatening conditions \u2014 United States, January\u2013May 2020","volume":"69","author":"Lange","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.11.003_b0050","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.15585\/mmwr.mm6936a4","article-title":"Delay or avoidance of medical care because of COVID-19\u2013related concerns \u2014 United States, June 2020","volume":"69","author":"Czeisler","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2022.11.003_b0055","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/MLR.0000000000001448","article-title":"Effects of the COVID-19 pandemic on outpatient providers in the United States","volume":"59","author":"Chatterji","year":"2021","journal-title":"Med Care"},{"key":"10.1016\/j.vaccine.2022.11.003_b0060","unstructured":"U.S. Food and Drug Administration. Biologics Effectiveness and Safety (BEST) Initiative. https:\/\/www.bestinitiative.org\/wp-content\/uploads\/2022\/01\/C19-Vaccine-Safety-AESI-Background-Rate-Report-2021.pdf; December 2021 [accessed 28 March 2022]."},{"key":"10.1016\/j.vaccine.2022.11.003_b0065","unstructured":"Safety Platform for Emergency vACcines (SPEAC). SO2-D2.1.2 Priority list of COVID-19 adverse events of special interest: quarterly update. https:\/\/brightoncollaboration.us\/wp-content\/uploads\/2021\/01\/SO2_D2.1.2_V1.2_COVID-19_AESI-update-23Dec2020-review_final.pdf; December 2020 [accessed 28 March 2022]."},{"key":"10.1016\/j.vaccine.2022.11.003_b0070","unstructured":"Safety Platform for Emergency vACcines (SPEAC). D2.3 Priority list of adverse events of special interest: COVID-19. https:\/\/brightoncollaboration.us\/wp-content\/uploads\/2021\/11\/SPEAC_D2.3_V2.0_COVID-19_20200525_public.pdf; 25 May 2020 [accessed 28 March 2022]."},{"key":"10.1016\/j.vaccine.2022.11.003_b0075","unstructured":"European Medicines Agency, European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Background rates of adverse events of special interest for monitoring COVID-19 vaccines. https:\/\/www.encepp.eu\/encepp\/viewResource.htm?id=37274; last updated 26 August 2021 [accessed 28 March 2022]."},{"key":"10.1016\/j.vaccine.2022.11.003_b0080","unstructured":"U.S. Food and Drug Administration, Center for Biologics Evaluation and Research (CBER) Surveillance Program. Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring: protocol. https:\/\/www.bestinitiative.org\/wp-content\/uploads\/2022\/01\/C19-Vax-Safety-AESI-Bkgd-Rate-Protocol-FINAL-2020.pdf; 12 January 2021 [accessed 28 March 2022]. Addendum: https:\/\/bestinitiative.org\/wp-content\/uploads\/2022\/01\/C19-Vax-Safety-AESI-Bkgd-Rate-Protocol-Addendum-2021.pdf."},{"issue":"28","key":"10.1016\/j.vaccine.2022.11.003_b0085","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1016\/j.vaccine.2021.05.016","article-title":"U.S. population-based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines","volume":"39","author":"Gubernot","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.11.003_b0090","unstructured":"Willame C, Dodd C, Gini R, Dur\u00e1n CE, Thomsen RM, Wang L, et al. Background rates of adverse events of special interest for monitoring COVID-19 vaccines. Zenodo. https:\/\/zenodo.org\/record\/5255870#.Ycy2hmjMI2x; 25 August 2021 [accessed 28 March 2022]."},{"key":"10.1016\/j.vaccine.2022.11.003_b0095","doi-asserted-by":"crossref","unstructured":"Nyberg F, Lindh M, Vanfleteren LEGW, Hammar N, Wettermark B, Sundstr\u00f6m J, et al. Adverse events of special interest for COVID-19 vaccines - background incidences vary by sex, age and time period and are affected by the pandemic. medRxiv. doi: 10.1101\/2021.10.04.21263507; 5 October 2020 [accessed 28 March 2022].","DOI":"10.1101\/2021.10.04.21263507"},{"key":"10.1016\/j.vaccine.2022.11.003_b0100","doi-asserted-by":"crossref","unstructured":"Burn E, Li X, Kostka K, Stewart HM, Reich C, Seager S, et al. Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: incidence between 2017 and 2019 and patient profiles from 25.4 million people in six European countries. medRxiv. doi: 10.1101\/2021.05.12.21257083; 17 September 2021 [accessed 28 March 2022].","DOI":"10.1002\/pds.5419"},{"key":"10.1016\/j.vaccine.2022.11.003_b0105","doi-asserted-by":"crossref","first-page":"e052019","DOI":"10.1136\/bmjopen-2021-052019","article-title":"Background incidence rates of hospitalisations and emergency department visits for thromboembolic and coagulation disorders in Ontario, Canada for COVID-19 vaccine safety assessment: a population-based retrospective observational study","volume":"11","author":"Nasreen","year":"2021","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.vaccine.2022.11.003_b0110","doi-asserted-by":"crossref","first-page":"e2024984","DOI":"10.1001\/jamanetworkopen.2020.24984","article-title":"Changes in health services use among commercially insured US populations during the COVID-19 pandemic","volume":"3","author":"Whaley","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.vaccine.2022.11.003_b0115","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2022.11.003_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2020.100742","article-title":"Thrombosis and coagulopathy in COVID-19","volume":"46","author":"G\u00f3mez-Mesa","year":"2021","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.11.003_b0125","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s12185-020-03029-y","article-title":"COVID-19-associated coagulopathy and disseminated intravascular coagulation","volume":"113","author":"Asakura","year":"2021","journal-title":"Int J Hematol"},{"issue":"33","key":"10.1016\/j.vaccine.2022.11.003_b0130","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1093\/eurheartj\/ehab314","article-title":"Spanish Investigators on Emergency Situations TeAm (SIESTA) network. Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome","volume":"42","author":"Mir\u00f3","year":"2021","journal-title":"Eur Heart J"},{"issue":"10300","key":"10.1016\/j.vaccine.2022.11.003_b0135","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0140-6736(21)00896-5","article-title":"Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study","volume":"398","author":"Katsoularis","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2022.11.003_b0140","doi-asserted-by":"crossref","first-page":"E426","DOI":"10.1148\/radiol.2021210777","article-title":"Pulmonary embolism in hospitalized patients with COVID-19: a multicenter study","volume":"301","author":"Riyahi","year":"2021","journal-title":"Radiology"},{"issue":"12","key":"10.1016\/j.vaccine.2022.11.003_b0145","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection","volume":"27","author":"Patone","year":"2021","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.vaccine.2022.11.003_b0150","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41591-022-01689-3","article-title":"Long-term cardiovascular outcomes of COVID-19","volume":"28","author":"Xie","year":"2022","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.vaccine.2022.11.003_b0155","doi-asserted-by":"crossref","first-page":"e778","DOI":"10.1212\/WNL.0000000000013184","article-title":"COVID-19 and risk of acute ischemic stroke among Medicare beneficiaries aged 65 years or older: self-controlled case series study","volume":"98","author":"Yang","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2022.11.003_b0160","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.15585\/mmwr.mm7035e5","article-title":"Association between COVID-19 and myocarditis using hospital-based administrative data \u2014 United States, March 2020\u2013January 2021","volume":"70","author":"Boehmer","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22013731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22013731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:22:26Z","timestamp":1759404146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22013731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0264410X22013731"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.11.003","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019\u20132020","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}